Catalyst Wire Dossier Catalyst Wire Dossier

Bimatoprost 0.01%

bimatoprost · AbbVie
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bimatoprost 0.01%, covering 2016-05-12 to 2016-05-12. Get the full timeline:

Most recent: Clinical Trial Update: Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml [Phase 4]

See pricing